CA Patent

CA2914049C — Pharmaceutical formulations of a hif hydroxylase inhibitor

Assigned to Fibrogen Inc · Expires 2021-10-12 · 5y expired

What this patent protects

The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7- phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.

USPTO Abstract

The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7- phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: CA2914049C
Jurisdiction: CA
Classification: —
Expires: 2021-10-12
Drug substance claim: No
Drug product claim: No
Assignee: Fibrogen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.